INKmune is an investigational cell-based innate immune therapy platform from INmune Bio designed to prime a patient's resting NK cells into tumor-killing memory-like NK cells. It is delivered by simple intravenous infusion and is being studied in metastatic castration-resistant prostate cancer and other NK-resistant tumor contexts. The program is clinical-stage and unapproved.
INmune Bio will present new Phase III clinical data for its CORDStrom cell therapy for recessive dystrophic epidermolysis bullosa. The webinar on February 26, 2026, will feature investigators discussing outcomes including skin score improvements and quality-of-life measures. CORDStrom represents a systemic, disease-modifying alternative to topical treatments for this rare skin disorder.
INmune Bio announced FDA alignment on Phase III registration program for XPro1595 in Alzheimer's disease and submitted regulatory packages for CORDStrom in rare disease treatment, marking key milestones toward commercialization.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06056791 |
Study of INKmune in Patients With mCRPC (CaRe Prostate) |
COMPLETED | PHASE1/PHASE2 |
| NCT05933070 |
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML |
TERMINATED | PHASE1 |
